Álvaro Murillo

Since I started my scientific career, I have systematically developed an expertise in Huntington’s Disease (HD). My research goal is to understand the molecular mechanisms that underpin HD and to translate that information into novel treatment avenues.
With this idea, I spent three years as student on a project aimed at removing mutant huntingtin aggregates by autophagy cell activation. In 2015 I joined Isabel Perez-Otano’s lab as PhD student at the Centre for Applied Medical Research in University of Navarra. My project was focused on the use of RNAi against GluN3A, a NMDA receptor, as a treatment for HD.
Two years after, we moved to the Institute of Neuroscience in Alicante where I studied temporal and cell populations GluN3A expression.
In 2020 I joined Vincent Dion’s lab in the UK DRI at Cardiff University. My aim is the use of CRISPR system in preclinical studies as a treatment for HD.